EZETIMIBE SANDOZ

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

EZETIMIBE

Dostępny od:

NOVARTIS ISRAEL LTD

Kod ATC:

C10AX09

Forma farmaceutyczna:

TABLETS

Skład:

EZETIMIBE 10 MG

Droga podania:

PER OS

Typ recepty:

Required

Wyprodukowano przez:

LEK PHARMACEUTICALS D.D., SLOVENIA

Dziedzina terapeutyczna:

EZETIMIBE

Wskazania:

Primary hypercholesterolemia: Ezetimibe Sandoz administered with an HMG-CoA reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. Homozygous familial hypercholesterolemia (HoFH): Ezetimibe Sandoz administered with a statin are indicated for use in patients with HoFH.Patients may also receive adjunctive treatments (e.g. LDL apheresis).Homozygous sitosterolemia (Phytosterolemia): Ezetimibe Sandoz are indicated for use in patients with homozygous familial sitosterolemia.

Data autoryzacji:

2019-07-09

Ulotka dla pacjenta

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS (PREPARATIONS) - 1986
THIS MEDICINE IS TO BE SUPPLIED UNDER
DOCTOR’S PRESCRIPTION ONLY
EZETIMIBE SANDOZ
®
TABLETS
ACTIVE SUBSTANCE AND ITS AMOUNT:
Each tablet contains:
ezetimibe 10 mg
For
a
list
of
inactive
ingredients
please
refer
to
‘Important
information about some of the ingredients of Ezetimibe Sandoz’
as well as section 6.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE.
•
This
leaflet
contains
concise
information
about
Ezetimibe
Sandoz. If you have any further questions, ask your doctor or
pharmacist.
•
This medicine has been prescribed for you. Do not pass it on
to others. It may harm them, even if their ailment seems similar
to yours.
1.
WHAT IS EZETIMIBE SANDOZ USED FOR?
Ezetimibe Sandoz is intended for patients with:
Primary hypercholesterolemia:
Ezetimibe Sandoz administered with an HMG CoA reductase
inhibitor (statin) or alone are indicated as adjunctive therapy to
diet for use in patients with primary (heterozygous familial and
non familial) hypercholesterolemia.
Homozygous familial hypercholesterolemia (HoFH):
Ezetimibe Sandoz administered with a statin are indicated for
use in patients with HoFH. Patients may also receive adjunctive
treatments (e.g. LDL apheresis).
Homozygous
sitosterolemia
(Phytosterolemia):
Ezetimibe
Sandoz is indicated for use in patients with homozygous familial
sitosterolemia.
THERAPEUTIC GROUP:
Ezetimibe is a member of a class of medicines called _ CAI _
(Cholesterol Absorption Inhibitors), which inhibits the intestinal
absorption of cholesterol.
2.
BEFORE YOU TAKE EZETIMIBE SANDOZ
DO NOT TAKE EZETIMIBE SANDOZ:
•
if you are allergic (hypersensitive) to ezetimibe or any of the
other ingredients of Ezetimibe Sandoz (see also section 6).
•
together with a statin, if you currently have liver problems.
•
together with a statin, if you are pregnant or breast feeding.
If you use Ezetimibe Sandoz together with a statin, please read
the package leaflet of that particular medicine.
If you